Rofecoxib's Selective Binding Mechanism
Rofecoxib (Vioxx) binds selectively to cyclooxygenase-2 (COX-2) over COX-1 due to structural differences in the enzymes' active sites. COX-2 has a larger hydrophobic pocket adjacent to the main catalytic channel, created by a valine residue (Val523 in mouse COX-2, equivalent to Val509 in human) replacing the bulkier arginine found in COX-1 (Arg120). This extra space accommodates rofecoxib's sulfonamide group, which fits snugly into the COX-2 pocket via hydrophobic interactions and hydrogen bonding with nearby residues like Ser530 and Thr585.[1][2]
How Rofecoxib Exploits the COX-2 Pocket
The drug's central furanone ring occupies the shared catalytic site of both enzymes, but its trifluoromethyl and sulfonamide substituents extend into the COX-2-specific side pocket. Molecular docking studies show these groups form stabilizing van der Waals contacts with Ile523, Phe381, and Phe518 in COX-2, boosting affinity. In COX-1, steric clash with Arg120 and Phe503 blocks this extension, reducing binding efficiency.[2][3]
Binding Affinity Data
Rofecoxib inhibits COX-2 with an IC50 of about 0.5–0.8 μM, versus 15–100 μM for COX-1, yielding a selectivity ratio of 50–266:1 favoring COX-2. This gap stems from slower dissociation from COX-2 (residence time ~hours) compared to COX-1.[1][4]
Comparison to Nonselective NSAIDs
Unlike ibuprofen or naproxen, which bind both enzymes equally via short carboxylic acid chains fitting the main channel, rofecoxib's diaryl heterocycle design targets the COX-2 mutation. Other coxibs like celecoxib use a sulfonamide that interacts similarly but with different pocket residues.[3]
Implications for Safety and Recall
High COX-2 selectivity minimized gastrointestinal risks from COX-1 inhibition but linked to cardiovascular events, as COX-2-derived prostaglandins regulate vascular health. Merck withdrew rofecoxib in 2004 after trials showed doubled heart attack risk.[4]
[1]: DrugPatentWatch.com (patent data on mechanism claims).
[2]: Kurumbail et al., Nature (1996). "Structural Basis for Selective Inhibition of Cyclooxygenase-2 by Anti-Inflammatory Agents."
[3]: Luong et al., Biochemistry (1996). "Flexibility of the NSAID Binding Site in the Structure of Human Cyclooxygenase-2."
[4]: FitzGerald & Patrono, NEJM (2001). "The Coxibs, Selective Inhibitors of Cyclooxygenase-2."